GLP-1 is the celebrity. Amylin is the second fullness signal now getting a lot more attention.
Cagrilintide is a long-acting amylin analog studied for appetite control and weight management.
It is designed to act like amylin, a natural hormone released after eating. Amylin helps tell the brain, “Food has arrived. You can slow down now.”
That simple signal is why cagrilintide has become one of the most watched peptides in next-generation weight-management research.
See Certiva Cagrilintide specifications →
Why is cagrilintide getting attention?
It follows a different path from GLP-1 while aiming at some of the same things people care about.
Appetite
Turns up the “I have eaten” signal
Amylin signaling helps the brain register that food has arrived.
Fullness
Helps a meal feel more satisfying
The pathway is connected with satiety and lower food intake.
Combination potential
Pairs naturally with GLP-1 research
CagriSema combines cagrilintide with semaglutide.
What is cagrilintide?
Cagrilintide is a man-made version of amylin, a hormone the body naturally releases after a meal.
The word “analog” simply means it is designed to copy a natural signal. The “long-acting” part means researchers changed the molecule so that the signal lasts much longer than natural amylin.
That matters because natural amylin disappears quickly. Cagrilintide was built to keep the same basic message active for longer.
You can think of it as a longer-lasting version of the body’s meal-finished message.
What does amylin do?
Amylin works alongside insulin after food is eaten. Its best-known jobs are easy to understand:
- it sends fullness signals to the brain;
- it can help reduce food intake;
- it slows how quickly food leaves the stomach; and
- it helps manage the rise in glucagon after a meal.
You do not need to memorize those terms. The big idea is simpler: amylin helps the body respond to a meal and know when enough food has arrived.
Cagrilintide is interesting because it gives researchers a longer-lasting way to study that signal.
Is cagrilintide a GLP-1?
No. Cagrilintide is not a GLP-1 receptor agonist.
Semaglutide follows the GLP-1 pathway. Cagrilintide follows the amylin pathway.
Both pathways can affect appetite and fullness, but they do not use the same receptors.
| Peptide | Main pathway | Simple way to remember it |
|---|---|---|
| Cagrilintide | Amylin | Strengthens a meal-finished signal |
| Semaglutide | GLP-1 | Strengthens a gut-to-brain fullness signal |
| Retatrutide | GIP + GLP-1 + glucagon | Sends three metabolic signals |
Different pathways are an advantage. They are the reason cagrilintide can be studied alone and alongside GLP-1 peptides.
Read the full side-by-side guide in cagrilintide vs semaglutide.
How much weight loss was reported with cagrilintide?
The clearest large-study number comes from REDEFINE 1, a 68-week Phase 3 trial.
When researchers estimated what would happen if everyone stayed on treatment:
- the cagrilintide group lost an average of 11.8% of starting body weight;
- the placebo group lost an average of 2.3%; and
- only 1.3% of the cagrilintide group stopped because of digestive side effects.
That is a meaningful result for a peptide working through the amylin pathway rather than GLP-1.
It also explains why cagrilintide is more than a supporting character in the weight-management pipeline. It produced its own result before being combined with semaglutide.
Novo Nordisk summarizes the cagrilintide result in its 2025 annual report.
What is CagriSema?
CagriSema combines cagrilintide and semaglutide.
The name comes from the two components:
- Cagri from cagrilintide; and
- Sema from semaglutide.
This is the commercial idea behind the combination: use two different fullness pathways instead of asking one pathway to do everything.
In REDEFINE 1, the combination produced greater average weight loss than either component alone when all groups were compared under the same trial.
| REDEFINE 1 result at 68 weeks | Average weight change if participants stayed on treatment |
|---|---|
| CagriSema | −22.7% |
| Semaglutide | −16.1% |
| Cagrilintide | −11.8% |
| Placebo | −2.3% |
The combination result is the reason people searching for “what is cagrilintide?” often find CagriSema next.
The peer-reviewed REDEFINE 1 study in The New England Journal of Medicine included 3,417 participants and tested the combination, both single components, and placebo.
Is CagriSema the same as Retatrutide plus Cagrilintide?
No. The names describe different combinations.
- CagriSema: cagrilintide + semaglutide
- Certiva Retatrutide + Cagrilintide research blend: retatrutide + cagrilintide
Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist. Semaglutide is a single GLP-1 receptor agonist. Switching one for the other creates a different blend.
Clear names matter. Buyers should always check the exact components and amounts on the product specification and batch documents.
What side effects appeared in cagrilintide research?
The most common reported side effects were digestive. They included:
- nausea;
- constipation;
- diarrhea; and
- vomiting.
In the cagrilintide arm of REDEFINE 1, these events were usually manageable, and the reported rate of stopping because of digestive side effects was low.
That is the useful takeaway for a simple guide: the most common effects were digestive, while most participants stayed in the trial.
Medical decisions about finished medicines belong with a licensed healthcare professional. Certiva supplies cagrilintide as a laboratory research reference, not as a finished prescription medicine.
Why are researchers interested in amylin now?
GLP-1 proved that gut and meal signals can have a major effect on appetite and body weight. Amylin opens a second door.
That creates several useful research questions:
- What can the amylin pathway do by itself?
- How does it compare with GLP-1?
- What happens when amylin and GLP-1 are studied together?
- Can different pathways produce a broader appetite and fullness response?
Cagrilintide sits in the middle of all four questions. That gives the molecule a clear place in both single-peptide and combination research.
What should a cagrilintide buyer check?
A popular molecule still needs good batch documents.
Before choosing a cagrilintide supplier, ask for:
- the exact molecule name;
- the vial specification and pack size;
- a Certificate of Analysis tied to the current lot;
- HPLC purity and identity information;
- storage, packaging, availability, and lead time; and
- stocked, bulk, or custom-quantity options.
Certiva supplies Cagrilintide in 5 mg and 10 mg vial specifications, with 10 vials per standard box. Bulk and custom quantities are available by inquiry.
The current batch report can be requested before an order. That lets a buyer compare the actual lot, specification, purity result, and documentation before making a decision.
Need help checking the paperwork? Read how to read a peptide COA in five minutes or see seven simple checks for choosing a peptide supplier. For a quote-ready commercial brief, use the 2026 amylin peptide supplier guide covering exact analogue, bulk format, batch evidence, packaging, and repeat supply.
Why the amylin pathway matters
Cagrilintide is a long-acting amylin analog studied for appetite control and weight management.
Its main advantage is easy to understand: it follows the amylin pathway instead of simply repeating GLP-1. That gives researchers a strong stand-alone peptide and a natural partner for combination studies.
The REDEFINE 1 results made the opportunity visible. Cagrilintide produced meaningful average weight loss on its own, while the CagriSema combination showed what can happen when amylin and GLP-1 work together.
Request Cagrilintide specifications, the current COA, and a quote
Tell Certiva the vial specification, quantity, destination country, and documentation you need. We will reply with current availability, batch information, lead time, bulk options, and a quote.
View Cagrilintide specifications · Compare Cagrilintide and Semaglutide · See Certiva quality standards
Request the current Cagrilintide COA + a quote →
Sources and further reading
- Novo Nordisk Annual Report 2025: cagrilintide and CagriSema results
- New England Journal of Medicine: REDEFINE 1
- PubMed: Cagrilintide lowers body weight through brain amylin receptors 1 and 3
Frequently asked questions
What is cagrilintide?
Cagrilintide is a long-acting amylin analog studied for appetite control and weight management.
Is cagrilintide a GLP-1?
No. Cagrilintide is an amylin analog. GLP-1 and amylin are different natural signals, but both can affect appetite, fullness, and food intake.
How much weight loss was reported with cagrilintide?
In the 68-week REDEFINE 1 trial, the cagrilintide group lost an estimated average of 11.8% of starting body weight when researchers calculated the effect if everyone stayed on treatment.
What is CagriSema?
CagriSema combines cagrilintide with semaglutide. It brings the amylin and GLP-1 pathways together in one research program.
What is the difference between CagriSema and Retatrutide plus Cagrilintide?
CagriSema is cagrilintide plus semaglutide. Certiva's Retatrutide plus Cagrilintide research blend contains two different components and should not be called CagriSema.
Can buyers request a Certiva cagrilintide COA before ordering?
Yes. Buyers can request the current batch COA, vial specifications, availability, bulk options, lead time, and a destination-based quote before ordering.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →